Loading…
Also known as Cannabidiol, CBD
Non-intoxicating cannabinoid that modulates the endocannabinoid system indirectly and acts on serotonin 5-HT1A receptors; studied for anxiety, inflammatory pain, and sleep disruption.
We link to relevant studies and leave interpretation to you and your healthcare professional.
Number of audited published findings for CBD Oil by condition. Drill into a pair page for the full breakdown.
Where people report using it and what trials suggest
Common claims the trials do not support
Cannabidiol with one strong approved indication (rare epilepsy syndromes) and widespread consumer uses that outrun the evidence; product quality is a known problem.
Safety notes: Interacts with liver enzymes (CYP3A4/2C19) — serious for many common drugs. Sedation, GI effects. Avoid with alcohol/high-dose alerts.
Evidence grades reflect study quality and consistency, not marketing claims.
Summaries of published trial results for this compound, grouped by condition. Numbers are reported exactly as the researchers published them — we never calculate or convert.
How to read this table
In short: benefit is what was observed; evidence is how much you should trust the observation. A “Benefit seen” tag on a weak study counts for far less than the same tag on a meta-analysis.
| Outcome measured | What trials found | Effect size | People studied | Duration | Type of evidence | Study |
|---|---|---|---|---|---|---|
| pain interference scores | Pain interference scores may have reduced by 1.52 points vs baseline in 117 dogs over 4-12 weeks, but evidence is very uncertain. (95% CI; -3.84 to 0.80, I2 = 89.59%, p = 0.20)Unclear | -1.52 | 117 | 4-12 weeks | Systematic review · 2023 | PMID 37781283 |
| pain severity scores | Pain severity scores may have reduced by 0.60 points vs baseline in 117 dogs over 4-12 weeks, but evidence is very uncertain. (95% CI; -1.51 to 0.31, I2 = 45.64%, p = 0.19)Unclear | -0.60 | 117 | 4-12 weeks | Systematic review · 2023 |
Associated conditions and community-reported outcomes, wrapped together on one page. Aggregates appear only once enough reports arrive.
How this compound is sold in the UK, and where our readers typically find it.
Retailer search links — we may earn commission on purchases at no cost to you. Commission never affects our evidence ratings.
In the UK, CBD products fall under the FSA novel foods list — buy from retailers listing an FSA-assessed product.
| Disabilities of the Arm, Shoulder, and Hand | Topical CBD improved disability scores compared to shea butter alone in 18 people over 2 weeks.Benefit seen | no number reported | 18 | 2 weeks | RCT · 2022 | PMID 35637038 |
| Range of motion, grip, and pinch strength | Topical CBD showed similar physical parameters compared to shea butter alone in 18 people over 2 weeks.No clear benefit | no number reported | 18 | 2 weeks | RCT · 2022 | PMID 35637038 |
| Single Assessment Numeric Evaluation | Topical CBD improved satisfaction scores compared to shea butter alone in 18 people over 2 weeks.Benefit seen | no number reported | 18 | 2 weeks | RCT · 2022 | PMID 35637038 |
| Visual Analog Scale pain | Topical CBD improved pain scores compared to shea butter alone in 18 people over 2 weeks.Benefit seen | no number reported | 18 | 2 weeks | RCT · 2022 | PMID 35637038 |